Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ARMPNASDAQ:BDRXOTCMKTS:BIXTOTCMKTS:HSTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$1.29-5.1%$1.46$0.90▼$3.42$46.67M0.8711,719 shs15,202 shsBDRXBiodexa Pharmaceuticals$1.41$1.69$1.14▼$74.00$51.53M1.15586,568 shs34,955 shsBIXTBioxytran$0.15+11.8%$0.16$0.06▼$0.23$15.03M1.82239,664 shs109,534 shsHSTCHST Global$0.83$0.76$0.23▼$1.11$47.95M-1.191,185 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals-0.73%+1.12%+21.97%-62.84%-62.84%BDRXBiodexa Pharmaceuticals+2.17%0.00%0.00%-65.36%+140,999,900.00%BIXTBioxytran+3.23%-10.53%-23.31%+65.68%+27.81%HSTCHST Global0.00%0.00%0.00%+13.70%-24.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARMPArmata Pharmaceuticals1.9397 of 5 stars3.53.00.00.01.61.70.0BDRXBiodexa Pharmaceuticals0.1513 of 5 stars0.03.00.00.00.00.00.6BIXTBioxytran0.67 of 5 stars0.05.00.00.00.61.70.0HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals 3.00Buy$7.00442.64% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/ABIXTBioxytran 0.00N/AN/AN/AHSTCHST Global 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.53M10.30N/AN/A($0.89) per share-1.45BDRXBiodexa Pharmaceuticals$83K620.81N/AN/A$42.56 per share0.03BIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$69.04M-$1.64N/AN/AN/AN/AN/A-60.91%N/ABDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/ABIXTBioxytran-$4.47M-$0.01N/A∞N/AN/AN/A-2,100.34%N/AHSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/ALatest BIXT, ARMP, BDRX, and HSTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/3/2025Q1 2025BIXTBioxytranN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ABIXTBioxytranN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A0.190.19BDRXBiodexa Pharmaceuticals0.022.16N/ABIXTBioxytranN/A0.030.03HSTCHST GlobalN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%BDRXBiodexa Pharmaceuticals17.51%BIXTBioxytranN/AHSTCHST GlobalN/AInsider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals85.50%BDRXBiodexa Pharmaceuticals0.34%BIXTBioxytran70.00%HSTCHST Global65.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals7036.18 million5.25 millionNot OptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableBIXTBioxytran2100.17 million26.44 millionNot OptionableHSTCHST Global157.77 million16.33 millionNot OptionableBIXT, ARMP, BDRX, and HSTC HeadlinesRecent News About These CompaniesHST Global Delays Yearly Report FilingApril 2, 2025 | tipranks.comHST Global Delays Form 10-K FilingMarch 31, 2025 | tipranks.comHST Global Inc HSTCNovember 15, 2024 | morningstar.comGST/HST Credit September 2024: Check Eligibility, Payment Dates & ScheduleOctober 2, 2024 | southarkansassun.comGST/HST Credit September 2024: Check Eligibility, Payment Dates & ScheduleOctober 2, 2024 | southarkansassun.comCanadians will soon receive GST/HST credit payments. How much?October 2, 2024 | msn.comCanadians will soon receive GST/HST credit payments. How much?October 2, 2024 | msn.comHost Hotels & Resorts, Inc (HST): Navigating Economic Cycles with Strategic ResilienceSeptember 26, 2024 | msn.comCKNW homepageSeptember 6, 2024 | globalnews.caVinaconex Investment and Tourism Development JSCSeptember 6, 2024 | morningstar.comLof International Dairy Products JSCSeptember 5, 2024 | morningstar.comHung Hau Agricultural Corp.August 31, 2024 | wsj.comHST Global Announces Details of Protocol Licensing for Health Matters InternationalAugust 19, 2024 | br.advfn.comViettel Global Investment JSC VGIMay 16, 2024 | morningstar.comGlobal Electrical Technology Corp.May 7, 2024 | wsj.comGlobal Surgery TrackApril 13, 2024 | bcm.eduViettel Global Investment JSCFebruary 23, 2024 | morningstar.comVNG Corp VNZFebruary 15, 2024 | morningstar.com2020 Land Rover Range Rover Sport ReviewDecember 17, 2023 | autoblog.comHST Global, Inc. (HSTC)November 23, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIXT, ARMP, BDRX, and HSTC Company DescriptionsArmata Pharmaceuticals NYSEAMERICAN:ARMP$1.29 -0.07 (-5.15%) As of 04:10 PM EasternArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Biodexa Pharmaceuticals NASDAQ:BDRX$1.41 0.00 (0.00%) As of 03:59 PM EasternBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Bioxytran OTCMKTS:BIXT$0.15 +0.02 (+11.77%) As of 03:48 PM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.HST Global OTCMKTS:HSTC$0.83 0.00 (0.00%) As of 05/8/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
